Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Simona Valletta and Dr Sarah Gooding, who were selected for the Translational Research Training in Hematology Program, a year-long training and mentoring experience by the American Society of Hematology and the European Hematology Association.

© Julie Stevens

We are pleased to announce that Dr Simona Valletta (Nerlov group) and Dr Sarah Gooding (Vyas group) at the MRC Molecular Haematology Unit has been selected by the American Society of Hematology (ASH) and the European Hematology Association (EHA) to participate as one of 20 early-career translational researchers in the joint 2020 Translational Research Training in Hematology (TRTH) program.

TRTH is a rigorous year-long training and mentoring experience that helps talented junior scientists build successful careers in translational hematology research. Under the guidance of international leaders, participants work to improve their research project in every sense, including design, adequate statistics, and how to get your work funded. TRTH aims to include participants at a specific stage in career development, namely being a trainee or junior faculty and hold an MD and/or PhD or biomedical PhD or pharmacy PharmD degree (or equivalents).

The TRTH year begins with a week-long Spring Course, designed to give participants a more profound understanding of translational research methodology and career development. Held in France, March 20-27, 2020, the Spring Course includes didactic and interactive sessions and one-on-one faculty mentoring that focuses on refining participants’ research proposals. TRTH participants will convene again at the 25th Congress of EHA in Frankfurt in June, where they will attend small group mentoring sessions. Finally, at the conclusion of the program, participants will present the status of their projects at the 2020 ASH Annual Meeting, December 5-8, in San Diego.

Simona was recently awarded an Intermediate Research Fellowship from the Kay Kendall Leukaemia Fund to study the effects of the ageing bone marrow microevironment in the prognosis of acute myeloid leukaemia (AML). Sarah is an Oxford-Celgene Translational Research Fellow using whole genome sequencing and single cell technologies to understand response and relapse to treatment in myeloma patients.

“This joint program gives scientists from all over the world with an interest in translational research the opportunity to become leaders in the field with the help of mentors,” said 2020 ASH President Stephanie Lee, MD, MPH, of Fred Hutchinson Cancer Research Center. “These talented junior researchers are rising stars in hematology.”

Co-founder of TRTH and EHA President John Gribben, MD, DSc, FRCP, FRCPath, FMedSci, says “We continue the long-term tradition of EHA mentorship for translational scientists and haematologists.  With the help of outstanding faculty members from EHA and ASH we look to ensure that these young stars of the future fulfil their full potential.”

Similar stories

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.